Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > New discovery could dramatically reduce leishmaniasis treatment doses and side effects: An 83 percent improvement in efficacy in the drug most commonly used to treat leishmaniasis

Abstract:
The Amphotericin B (AmB) is the main active ingredient in the most effective drug used to treat leishmaniasis, a disease which in the Western world mainly affects dogs, but in developing countries affects over 12 million people, with more than 70,000 deaths per year. The cost of treating humans with AmB surpasses $5,000 per patient, the treatment is extensive (2-hour sessions every day during 21 days), and the side effects are frequent and many times patients must be hospitalised.

New discovery could dramatically reduce leishmaniasis treatment doses and side effects: An 83 percent improvement in efficacy in the drug most commonly used to treat leishmaniasis

Barcelona, Spain | Posted on November 5th, 2013

Researchers from the University of Miami, Florida and the Universitat Autňnoma de Barcelona have developed a method which allows to drastically reduce the drug dose, since it improves its efficacy 83%, multiplies by 10 the capacity of the drug to attack cell infected by the parasite which provokes the disease, and significantly reduces the toxicity of the parasite. The method has been successfully tested on mice models of leishmaniasis.

The complex compound acts through the action of the PDD nanoparticle, a substance measuring some 10 nanometres in diameter which is fit into the active principle, Amphotericin B, and guides it selectively to the cells harbouring the parasite. Scientists observed how, while the usual complete dose of the drug requires over 12 days to reduce the skin lesions caused by the disease, one dose of the complex compound with only 17% of the complete dose of the drug improves skin lesions in two or three days. Moreover, the complex compound acts as a therapeutic vaccine which activates the immune system against the reservoir cells hosting the parasite.

The PDD substance has been used in previous trials with people with the aim of improving the response of their immune system to other diseases. Now there is a need for clinical trials with humans in order to verify its safety as an adjuvant in the treatment of leishmaniasis. If its safety in humans is confirmed, it will also reduce the cost of the treatment drastically, and this is a key element in reducing mortality rates in developing countries.

The research, recently published in the Journal of Infectious Diseases, included the participation of lecturer Jordi Alberola and Dr Alhelí Rodríguez, from the Department of Pharmacology, Therapeutics and Toxicology and the Drug Analysis Service of the UAB.

####

For more information, please click here

Contacts:
Jordi Alberola

34-935-811-532

Copyright © Universitat Autonoma de Barcelona

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New synthesis method may shape future of nanostructures, clean energy: Findings advance efficient solar spliting of water into hydrogen fuel September 2nd, 2014

Accounting for Biological Aggregation in Heating and Imaging of Magnetic Nanoparticles September 2nd, 2014

Engineers develop new sensor to detect tiny individual nanoparticles September 2nd, 2014

Future solar panels September 2nd, 2014

Nanomedicine

UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique: Oil-and-water approach from Richmond's UO lab to spark new line of versatile peptoid nanosheets September 2nd, 2014

Accounting for Biological Aggregation in Heating and Imaging of Magnetic Nanoparticles September 2nd, 2014

Nano-forests to reveal secrets of cells September 2nd, 2014

Nanoscale assembly line August 29th, 2014

Discoveries

Secure Computing for the ‘Everyman': Quantum computing goes to market in tech transfer agreement with Allied Minds September 2nd, 2014

Cool Calculations for Cold Atoms: New theory of universal three-body encounters September 2nd, 2014

UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique: Oil-and-water approach from Richmond's UO lab to spark new line of versatile peptoid nanosheets September 2nd, 2014

Future solar panels September 2nd, 2014

Announcements

New synthesis method may shape future of nanostructures, clean energy: Findings advance efficient solar spliting of water into hydrogen fuel September 2nd, 2014

Accounting for Biological Aggregation in Heating and Imaging of Magnetic Nanoparticles September 2nd, 2014

Engineers develop new sensor to detect tiny individual nanoparticles September 2nd, 2014

Future solar panels September 2nd, 2014

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals

UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique: Oil-and-water approach from Richmond's UO lab to spark new line of versatile peptoid nanosheets September 2nd, 2014

New synthesis method may shape future of nanostructures, clean energy: Findings advance efficient solar spliting of water into hydrogen fuel September 2nd, 2014

Engineers develop new sensor to detect tiny individual nanoparticles September 2nd, 2014

Future solar panels September 2nd, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE